Amgen Enterprise Value vs Operating Income Analysis

AMGN Stock

USD 265.51 1.77 0.66%

Amgen financial indicator trend analysis is way more than just evaluating Amgen Inc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amgen Inc is a good investment. Please check the relationship between Amgen Enterprise Value and its Operating Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

Enterprise Value vs Operating Income

Enterprise Value vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amgen Inc Enterprise Value account and Operating Income. At this time, the significance of the direction appears to have strong relationship.

The correlation between Amgen's Enterprise Value and Operating Income is 0.66. Overlapping area represents the amount of variation of Enterprise Value that can explain the historical movement of Operating Income in the same time period over historical financial statements of Amgen Inc, assuming nothing else is changed. The correlation between historical values of Amgen's Enterprise Value and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Enterprise Value of Amgen Inc are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Enterprise Value i.e., Amgen's Enterprise Value and Operating Income go up and down completely randomly.

Correlation Coefficient

0.66

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Enterprise Value

Enterprise Value (or EV) is usually referred to as Amgen theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Amgen Inc debt, but would also pocket its cash. Enterprise Value is more accurate representation of Amgen value than its market capitalization because it takes into account all of Amgen Inc existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.

Operating Income

Operating Income is the amount of profit realized from Amgen Inc operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Amgen Inc is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from Amgen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amgen Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

At this time, Amgen's Selling General Administrative is very stable compared to the past year. As of the 15th of April 2024, Tax Provision is likely to grow to about 1.4 B, while Enterprise Value Over EBITDA is likely to drop 9.83.

	2021	2022	2023	2024 (projected)
Interest Expense	1.2B	1.4B	2.9B	3.0B
Depreciation And Amortization	3.4B	3.4B	4.1B	4.3B

Interest Expense Depreciation And Amortization

Amgen fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Inventory	Accounts Payable	Common Stock Total Equity	Short Term Investments	Common Stock
Total Assets		0.93	0.74	0.81	0.33	0.65	0.94	-0.4	0.67	0.86	0.63	0.35	0.78	-0.49	0.92	-0.19	0.47	0.91	0.63	0.52	0.26	0.76	0.81	0.79	0.37	0.77
Short Long Term Debt Total	0.93		0.89	0.91	-0.01	0.47	0.99	-0.61	0.83	0.95	0.84	0.02	0.94	-0.55	0.99	-0.25	0.72	0.99	0.81	0.21	0.12	0.95	0.82	0.64	0.08	0.6
Other Current Liab	0.74	0.89		0.95	-0.37	0.39	0.85	-0.88	0.93	0.92	0.95	-0.3	0.99	-0.73	0.92	-0.21	0.84	0.94	0.9	-0.07	-0.06	0.93	0.88	0.58	-0.29	0.54
Total Current Liabilities	0.81	0.91	0.95		-0.23	0.47	0.88	-0.81	0.87	0.9	0.83	-0.12	0.94	-0.76	0.92	-0.29	0.73	0.95	0.82	0.1	0.25	0.88	0.89	0.67	-0.12	0.63
Total Stockholder Equity	0.33	-0.01	-0.37	-0.23		0.39	0.07	0.66	-0.35	-0.12	-0.44	0.88	-0.29	0.37	-0.05	0.17	-0.51	-0.09	-0.36	0.79	0.36	-0.27	-0.11	0.31	0.88	0.36
Property Plant And Equipment Net	0.65	0.47	0.39	0.47	0.39		0.46	-0.32	0.42	0.47	0.21	0.4	0.4	-0.53	0.48	0.22	0.1	0.49	0.35	0.63	0.28	0.3	0.59	0.96	0.27	0.95
Net Debt	0.94	0.99	0.85	0.88	0.07	0.46		-0.53	0.76	0.93	0.79	0.09	0.89	-0.51	0.98	-0.32	0.68	0.97	0.76	0.27	0.17	0.92	0.8	0.63	0.16	0.59
Retained Earnings	-0.4	-0.61	-0.88	-0.81	0.66	-0.32	-0.53		-0.85	-0.71	-0.81	0.56	-0.82	0.79	-0.66	0.13	-0.74	-0.7	-0.79	0.33	0.11	-0.72	-0.76	-0.46	0.62	-0.43
Cash	0.67	0.83	0.93	0.87	-0.35	0.42	0.76	-0.85		0.85	0.88	-0.31	0.94	-0.58	0.85	0.08	0.79	0.87	0.87	-0.1	-0.1	0.89	0.77	0.56	-0.32	0.51
Non Current Assets Total	0.86	0.95	0.92	0.9	-0.12	0.47	0.93	-0.71	0.85		0.88	-0.18	0.95	-0.65	0.96	-0.26	0.74	0.96	0.83	0.04	0.01	0.94	0.85	0.65	-0.14	0.61
Non Currrent Assets Other	0.63	0.84	0.95	0.83	-0.44	0.21	0.79	-0.81	0.88	0.88		-0.44	0.95	-0.61	0.86	-0.22	0.9	0.86	0.91	-0.24	-0.28	0.93	0.74	0.39	-0.39	0.34
Cash And Short Term Investments	0.35	0.02	-0.3	-0.12	0.88	0.4	0.09	0.56	-0.31	-0.18	-0.44		-0.26	0.21	0.0	0.09	-0.48	-0.03	-0.34	0.94	0.49	-0.28	-0.01	0.35	0.97	0.39
Net Receivables	0.78	0.94	0.99	0.94	-0.29	0.4	0.89	-0.82	0.94	0.95	0.95	-0.26		-0.65	0.95	-0.17	0.84	0.96	0.91	-0.04	-0.04	0.97	0.84	0.58	-0.23	0.53
Common Stock Shares Outstanding	-0.49	-0.55	-0.73	-0.76	0.37	-0.53	-0.51	0.79	-0.58	-0.65	-0.61	0.21	-0.65		-0.61	0.39	-0.5	-0.65	-0.6	-0.07	-0.14	-0.51	-0.81	-0.68	0.31	-0.65
Non Current Liabilities Total	0.92	0.99	0.92	0.92	-0.05	0.48	0.98	-0.66	0.85	0.96	0.86	0.0	0.95	-0.61		-0.26	0.72	1.0	0.81	0.2	0.07	0.93	0.88	0.67	0.04	0.62
Other Current Assets	-0.19	-0.25	-0.21	-0.29	0.17	0.22	-0.32	0.13	0.08	-0.26	-0.22	0.09	-0.17	0.39	-0.26		-0.2	-0.27	-0.13	0.06	-0.26	-0.2	-0.28	0.03	-0.01	0.05
Other Stockholder Equity	0.47	0.72	0.84	0.73	-0.51	0.1	0.68	-0.74	0.79	0.74	0.9	-0.48	0.84	-0.5	0.72	-0.2		0.73	0.96	-0.31	-0.25	0.84	0.59	0.24	-0.42	0.18
Total Liab	0.91	0.99	0.94	0.95	-0.09	0.49	0.97	-0.7	0.87	0.96	0.86	-0.03	0.96	-0.65	1.0	-0.27	0.73		0.83	0.18	0.11	0.93	0.89	0.68	0.01	0.63
Property Plant And Equipment Gross	0.63	0.81	0.9	0.82	-0.36	0.35	0.76	-0.79	0.87	0.83	0.91	-0.34	0.91	-0.6	0.81	-0.13	0.96	0.83		-0.13	-0.16	0.87	0.73	0.47	-0.32	0.43
Total Current Assets	0.52	0.21	-0.07	0.1	0.79	0.63	0.27	0.33	-0.1	0.04	-0.24	0.94	-0.04	-0.07	0.2	0.06	-0.31	0.18	-0.13		0.5	-0.09	0.22	0.6	0.89	0.61
Short Term Debt	0.26	0.12	-0.06	0.25	0.36	0.28	0.17	0.11	-0.1	0.01	-0.28	0.49	-0.04	-0.14	0.07	-0.26	-0.25	0.11	-0.16	0.5		-0.07	0.05	0.31	0.47	0.32
Inventory	0.76	0.95	0.93	0.88	-0.27	0.3	0.92	-0.72	0.89	0.94	0.93	-0.28	0.97	-0.51	0.93	-0.2	0.84	0.93	0.87	-0.09	-0.07		0.74	0.47	-0.19	0.4
Accounts Payable	0.81	0.82	0.88	0.89	-0.11	0.59	0.8	-0.76	0.77	0.85	0.74	-0.01	0.84	-0.81	0.88	-0.28	0.59	0.89	0.73	0.22	0.05	0.74		0.77	-0.05	0.76
Common Stock Total Equity	0.79	0.64	0.58	0.67	0.31	0.96	0.63	-0.46	0.56	0.65	0.39	0.35	0.58	-0.68	0.67	0.03	0.24	0.68	0.47	0.6	0.31	0.47	0.77		0.24	0.99
Short Term Investments	0.37	0.08	-0.29	-0.12	0.88	0.27	0.16	0.62	-0.32	-0.14	-0.39	0.97	-0.23	0.31	0.04	-0.01	-0.42	0.01	-0.32	0.89	0.47	-0.19	-0.05	0.24		0.26
Common Stock	0.77	0.6	0.54	0.63	0.36	0.95	0.59	-0.43	0.51	0.61	0.34	0.39	0.53	-0.65	0.62	0.05	0.18	0.63	0.43	0.61	0.32	0.4	0.76	0.99	0.26

Click cells to compare fundamentals

Amgen Account Relationship Matchups

Amgen fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	59.7B	62.9B	61.2B	65.1B	97.2B	102.0B
Short Long Term Debt Total	29.9B	33.0B	33.3B	38.9B	64.6B	67.8B
Other Current Liab	8.5B	10.1B	10.7B	12.5B	15.4B	16.1B
Total Current Liabilities	12.8B	11.7B	12.2B	15.7B	18.4B	19.3B
Total Stockholder Equity	9.7B	9.4B	6.7B	3.7B	6.2B	12.3B
Property Plant And Equipment Net	4.9B	4.9B	5.2B	5.4B	5.9B	3.6B
Net Debt	23.9B	26.7B	25.3B	31.3B	53.7B	56.4B
Retained Earnings	(21.3B)	(21.4B)	(24.6B)	(28.6B)	(26.5B)	(25.2B)
Cash	6.0B	6.3B	8.0B	7.6B	10.9B	11.5B
Non Current Assets Total	41.3B	41.8B	41.8B	42.9B	66.8B	70.2B
Non Currrent Assets Other	2.2B	5.6B	6.5B	5.9B	9.6B	10.1B
Cash And Short Term Investments	8.9B	10.6B	8.0B	9.3B	10.9B	10.5B
Net Receivables	4.1B	4.5B	4.9B	5.6B	7.9B	8.3B
Common Stock Shares Outstanding	609M	590M	573M	541M	538M	759.2M
Liabilities And Stockholders Equity	59.7B	62.9B	61.2B	65.1B	97.2B	102.0B
Non Current Liabilities Total	37.2B	41.9B	42.3B	45.8B	72.5B	76.2B
Other Current Assets	1.9B	2.1B	2.4B	2.4B	281M	267.0M
Other Stockholder Equity	(528M)	(985M)	18.2B	21.7B	25.0B	26.2B
Total Liab	50.0B	53.5B	54.5B	61.5B	90.9B	95.5B
Property Plant And Equipment Gross	4.9B	4.9B	14.0B	14.7B	15.7B	16.5B
Total Current Assets	18.4B	21.1B	19.4B	22.2B	30.3B	15.2B
Accumulated Other Comprehensive Income	(528M)	(985M)	(796M)	(231M)	(289M)	(274.6M)
Short Term Debt	3.0B	91M	87M	1.6B	1.4B	1.0B
Inventory	3.6B	3.9B	4.1B	4.9B	9.5B	10.0B
Accounts Payable	1.4B	1.4B	1.4B	1.6B	1.6B	1.7B
Common Stock Total Equity	31.5B	31.8B	32.1B	32.5B	37.4B	27.1B
Short Term Investments	2.9B	4.4B	48M	1.7B	10.9B	12.2B
Common Stock	31.5B	31.8B	32.1B	32.5B	33.1B	27.5B
Other Assets	955M	1.3B	6.5B	2.2B	2.5B	1.4B
Long Term Debt	27.0B	32.9B	33.2B	37.4B	63.2B	66.3B
Property Plant Equipment	4.9B	4.9B	5.2B	5.4B	6.2B	5.3B
Good Will	14.7B	14.7B	14.9B	15.5B	18.6B	14.4B
Intangible Assets	19.4B	16.6B	15.2B	16.1B	32.6B	34.3B
Other Liab	9.9B	9.0B	9.1B	7.9B	9.1B	5.1B
Net Tangible Assets	(24.4B)	(21.9B)	(23.4B)	(27.9B)	(25.2B)	(23.9B)
Retained Earnings Total Equity	(21.3B)	(21.4B)	(24.6B)	(28.6B)	(25.8B)	(24.5B)
Long Term Debt Total	27.0B	32.9B	33.2B	37.4B	43.0B	29.9B
Non Current Liabilities Other	9.6B	9.0B	2.5B	2.7B	2.3B	2.2B

Pair Trading with Amgen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Amgen Stock

0.78

VRTX

Vertex Pharmaceuticals Financial Report 6th of May 2024

Pair Corr

Moving against Amgen Stock

0.82	NVO	Novo Nordisk AS Financial Report 2nd of May 2024	Pair Corr
0.82	RZLT	Rezolute Trending	Pair Corr
0.75	ERAS	Erasca Inc Financial Report 20th of May 2024	Pair Corr
0.72	CCCC	C4 TherapeuticsInc Financial Report 2nd of May 2024	Pair Corr
0.71	CELC	Celcuity LLC Financial Report 20th of May 2024	Pair Corr

The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.

The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:

How To Invest In Amgen

Details

Is Amgen Stock a good investment?

Details

What is Amgen's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

Note that the Amgen Inc information on this page should be used as a complementary analysis to other Amgen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for Amgen Stock analysis

When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.

	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios

Is Amgen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.52)

Dividend Share

8.52

Earnings Share

12.48

Revenue Per Share

52.692

Quarterly Revenue Growth

0.198

The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amgen Enterprise Value vs Operating Income Analysis

Enterprise Value vs Operating Income

Enterprise Value vs Operating Income Correlation Analysis

Correlation Coefficient

Enterprise Value

Operating Income

Amgen fundamental ratios Correlations

Amgen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amgen fundamental ratios Accounts

Pair Trading with Amgen

Moving together with Amgen Stock

Moving against Amgen Stock

Complementary Tools for Amgen Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Non Current Liabilities Total
Net Debt	+ 0.99	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Short Long Term Debt Total
Net Receivables	+ 0.99	Other Current Liab
Common Stock	+ 0.99	Common Stock Total Equity

Retained Earnings	- 0.88	Other Current Liab
Cash	- 0.85	Retained Earnings
Net Receivables	- 0.82	Retained Earnings
Accounts Payable	- 0.81	Common Stock Shares Outstanding
Non Currrent Assets Other	- 0.81	Retained Earnings
Retained Earnings	- 0.81	Total Current Liabilities